Generic Name: Aricept

What is Aricept?

Dosering Bijwerkingen Wanneer mag u dit geneesmiddel niet gebruiken. Dosering Aricept is alleen op recept verkrijgbaar in tabletten van 5 mg en 10 mg. The above information is provided for general informational and educational purposes only.

Individual plans may vary and formulary information changes. Contact the applicable plan provider for the most current information. To: By clicking send, you acknowledge that you have permission to email the recipient with this information.

If you log out, you will be required to enter your username and password the next time you visit. To view formulary information first create a list of plans. Create Your List of Plans The above information is provided for general informational and educational purposes only. View explanations for tiers and restrictions Tier Description 1 This drug is available at the lowest co-pay. Most commonly, these are generic drugs.

AriceptAlan, a retired school caretaker, has been prescribed Aricept after being diagnosed with Alzheimer's four years ago. Alzheimer's protest marchNice rejected an appeal last month over its guidance that states that sufferers with early or late stage Alzheimer's disease should not have access to Aricept donepezilReminyl galantamine or Exelon rivastigmine. Action over drugs denial Medical browser.

The page has not loaded completely and some content and functionality are corrupted. Please reload the page or if you are running ad blocking disable it. Donepezil hydrochloride marketed as Aricept is one of a group of three drugs for people with Alzheimer's disease called cholinesterase inhibitors. The other two are called rivastigmine common brand name Exelon and galantamine hydrobromide common brand name Reminyl.

For the purposes of this information sheet, donepezil hydrochloride will be referred to as Aricept, since it is the brand most people will be familiar with, although other brands may become available when the UK patent expires in February 2012. Aricept is the name given to the particular brand of donepezil hydrochloride produced by a company called Eisai Ltd. It is licensed for the treatment of mild to moderately severe Alzheimer's disease.

Aricept is not claimed to be a cure for Alzheimer's disease. It treats the symptoms only and there is no evidence that it could halt or reverse the process of brain cell damage that causes Alzheimer's disease.

Alzheimer Scotland - Action on Dementia is a company limited by guarantee, registered in Scotland 149069. Hoe gebruikt u Aricept.

How should I take Aricept?

Donepezil acts as a centrally acting reversible acetylcholinesterase inhibitor. Food and Drug Administration also approved donepezil for treatment of mild, moderate and severe dementia in Alzheimer's disease. Side effects improved with continued use. These symptoms may appear more frequent when initiating treatment or increasing the donepezil dose.

Although occurrence of seizures is rare, people who have a predisposition to seizures should be treated with caution.

This results in an increased acetylcholine concentrations at cholinergic synapses. The precise mechanism of action of donepezil in patients with Alzheimer's disease is not fully understood. Just the severity of the loss of cholinergic neurons of the central nervous system CNS has been found to correlate with the severity of cognitive impairment.

What should I avoid while taking Aricept?

This drug may make you dizzy or drowsy. Do not drive, use machinery, or do any activity that requires alertness until you are sure you can perform such activities safely. Donepezil may cause a condition that affects the heart rhythm QT prolongation. The risk of QT prolongation may be increased if you have certain medical conditions or are taking other drugs that may cause QT prolongation.

Before using donepezil, tell your doctor or pharmacist of all the drugs you take and if you have any of the following conditions: certain heart problems heart failure, slow heartbeat, QT prolongation in the EKGfamily history of certain heart problems QT prolongation in the EKG, sudden cardiac death.

Low levels of potassium or magnesium in the blood may also increase your risk of QT prolongation. Talk to your doctor about using donepezil safely.

Aricept side effects

Age: No formal pharmacokinetic study was conducted to examine age-related differences in the pharmacokinetics of ARICEPT. Gender and Race: No specific pharmacokinetic study was conducted to investigate the effects of gender and race on the disposition of ARICEPT.

However, retrospective pharmacokinetic analysis and population pharmacokinetic analysis of plasma donepezil concentrations measured in patients with Alzheimer's disease indicates that gender and race Japanese and Caucasians did not affect the clearance of ARICEPT to an important degree.

When given in combination with memantine, donepezil increased the incidence and severity of memantine-induced neurodegeneration. The effectiveness of ARICEPT as a treatment for Alzheimer's disease is demonstrated by the results of randomized, double-blind, placebo-controlled clinical investigations.

Study Outcome Measures: In each study, the effectiveness of treatment with ARICEPT was evaluated using a dual outcome assessment strategy.

Common Aricept ide effects may include:

  • Learn causes, symptoms, treatments, diagnosis, and little-known facts about Alzheimer's disease AD and the brain disorders it can mimic.

  • The plasma protein binding of the active metabolite 6-O-desmethyldonepezil is not known.

  • Donepezil should not be used inWomen who are breastfeeding.

  • Drug interactions may change how your medications work or increase your risk for serious side effects.

Time Course of the Change from Baseline in SIB Score for Patients Completing 6 Months of Treatment. Figure 8 illustrates the cumulative percentages of patients from each of the two treatment groups who attained the measure of improvement in SIB score shown on the X-axis.

While patients assigned both to ARICEPT and to placebo have a wide range of responses, the curves show that the ARICEPT group is more likely to show a greater improvement in cognitive performance. Cumulative Percentage of Patients Completing 6 Months of Double-blind Treatment with Particular Changes from Baseline in SIB Scores.

Where can I get more information?

  • It is at this point that most if not all insurance carriers will simply refuse to offer coverage to the applicant.

  • Promising results indicate that 2-73 might even help return the patient to a functioning level of cognition in essence, stopping the decline of Alzheimer's in its tracks.